N/A N=36 Durolane SJ for Treatment of Rhizarthrosis
Rhizarthrosis
Primary: Change From Baseline in Pain Measured by the VAS Scale — -2.00 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes
Type 2 Diabetes
Primary: Evaluate the Impact of Acipimox on Exercise Parameters in People With Type 2 Diabetes: VO2 Kinetics — 51.4; 53.3 seconds
Phase 3 N=168 Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
COVID
Primary: Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients: — 10; 9; 18; 7 Participants — p=<0.025
Phase 2 N=17 A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
COVID-19
Primary: Time to Improvement in Oxygenation — 4 Days
Phase 2 N=30 Baked Milk Oral Immunotherapy for Cow's Milk Allergy
Cow's Milk Allergy
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 15; 11 Participants
N/A N=23 Support for Perinatal Adherence and Depression
Human Immunodeficiency Virus · Depression
Primary: Adherence to Antiretroviral Therapy Per Self-Report — 85.3; 79.0; 92.8; 77.8 percentage of self-reported adherence — p=0.11
Phase 1 N=71 Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study
Obesity · GERD
Primary: Pantoprazole Apparent Oral Clearance — 0.42; 0.29; 0.23 L/hr/kg
N/A N=30 TD01 Master Study (Safety and Efficacy Study)
ICD/CRT-D Indication
Primary: TD01 Pacing Threshold — 0.5 V
N/A N=178 Family Automated Voice Reorientation Study
Delirium · Cognitive Impairment · Health, Subjective
Primary: Delirium-free Days — 8.4; 7.2 days
N/A N=294 Monitoring and Peer Support to Improve Treatment Adherence and Outcomes
Chronic Obstructive Pulmonary Disease · Obstructive Sleep Apnea
Primary: Change in CPAP Adherence at 6 Weeks — 7.4; 6.3 hours per night of CPAP use
Phase 2 N=44 Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Recurrent Colorectal Carcinoma · Stage IVA Colorectal Cancer · Stage IVB Colorectal Cancer
Primary: To Examine the Adverse Event Profile — 21; 20; 17; 16 participants
Phase 3 N=105 KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
Mucocutaneous Lymph Node Syndrome
Primary: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. — 25; 40 Participants
N/A N=129 Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study
Gastroesophageal Reflux Disease · Hiatal Hernia
Primary: Number of Participants With a Clinically Significant Reduction in Gastroesophageal Reflux Disease (GERD) Symptoms (Specifically "Troublesome" Regurgitation With or…
Phase 3 N=2,964 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Anaemia · Aspergillosis, Allergic Bronchopulmonary
Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis…
Phase 4 N=365 EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)
Heart Failure
Primary: Change in NT-proBNP — 0.14; 0.19 unitless — p=0.45